ATTEND EVIDENCE EU CONGRESS

 

The industry is rapidly changing, which provides a unique set of challenges for those developing and manufacturing biosimilars and generic medicines. Gain true insight on winning development, manufacturing, clinical and commercialisation strategies for biosimilars and generics in the global market.

Navigate the challenges in the clinic, the manufacture and development of biosimilar and generic medicines as well as explore the commercial aspects of the industry. This is your best chance to find out where the industry growth opportunities lie and what role they can play in your portfolio.

WHO ATTENDS?

Heads of:

  • HTA 

  • Market Access 

  • Health Economics 

  • Outcomes Research 

  • Health Policy 

  • Epidemiology 

  • Pricing & Reimbursement

  • Pharmacoeconomics 

  • Clinical trials 

  • Clinical research 

  • Post marketing Surveillance 

  • Medical Affairs 

  • Pharmacoepidemiology

 WHY ATTEND?

  • Hear how RWE is shaping up decision making in healthcare

  • Understand the latest trends impacting evidence requirements for new drugs

  • Integrate payer expectations early in product development & market access strategies

  • Develop successful and transparent observational studies that optimize the commercialization of your medicine

  • Gain big value from your big data: assess collection, interpretation and communication strategies

  • Hear about new initiatives to combat low success rates of product submissions

  • Review the enabling technologies in evidence generation

  • Plan successful patient registry or PRO programmes

  • Discuss how to generate, apply and present ‘real world’ evidence to maximise patient access

  • Network with pioneers, influencers and innovators and return to your company with new ideas and relationships​

BOOK NOW

 

 

Evidence Europe Congress